Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Up 164.9% in March

Jaguar Health, Inc. (NASDAQ:JAGX) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 19,710,000 shares, an increase of 164.9% from the March 15th total of 7,440,000 shares. Based on an average trading volume of 40,390,000 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Jaguar Health in a research note on Saturday, April 6th. They set a “sell” rating on the stock.

Jaguar Health Trading Up 28.9 %

JAGX opened at $0.12 on Thursday. Jaguar Health has a fifty-two week low of $0.05 and a fifty-two week high of $1.22. The company’s 50-day moving average price is $0.08 and its 200 day moving average price is $0.19. The company has a current ratio of 2.00, a quick ratio of 1.34 and a debt-to-equity ratio of 6.33.

Institutional Investors Weigh In On Jaguar Health

Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new stake in shares of Jaguar Health in the first quarter valued at approximately $1,079,000. Millennium Management LLC boosted its holdings in Jaguar Health by 152.3% during the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock worth $157,000 after buying an additional 321,795 shares in the last quarter. Virtu Financial LLC boosted its holdings in Jaguar Health by 76.1% during the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock worth $162,000 after buying an additional 99,073 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Jaguar Health by 141.7% during the third quarter. Vanguard Group Inc. now owns 192,335 shares of the biotechnology company’s stock worth $50,000 after buying an additional 112,770 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after buying an additional 141,796 shares in the last quarter. Institutional investors and hedge funds own 12.04% of the company’s stock.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.